申请人:Pfizer Inc.
公开号:US20160221989A1
公开(公告)日:2016-08-04
The present invention relates to compounds of Formula I
described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.
本发明涉及描述如下的化合物以及其药学上可接受的盐,并且涉及它们在医学上的应用,特别是作为Trk拮抗剂。